Australia's most trusted
source of pharma news
Friday, 25 October 2024
Posted 10 July 2024 AM
There's still hope that Apellis' geographic atrophy (GA) treatment Syfovre could hit the Australian market despite a continuous back and forth to get the drug over the line in Europe.
It's nearing a year-and-a-half since the TGA accepted a Type C application, also known as a new indication application, for Syfovre in GA, a leading cause of blindness.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.